Effect of Genetic Variation on the Formation of Hepatocarcinogenic Metabolites of Trichloroethylene Using Chloral Hydrate Studies (an Interdisciplinary Approach) by Bronley-DeLancey, Apryl
Medical University of South Carolina 
MEDICA 
MUSC Theses and Dissertations 
2005 
Effect of Genetic Variation on the Formation of 
Hepatocarcinogenic Metabolites of Trichloroethylene Using 
Chloral Hydrate Studies (an Interdisciplinary Approach) 
Apryl Bronley-DeLancey 
Medical University of South Carolina 
Follow this and additional works at: https://medica-musc.researchcommons.org/theses 
Recommended Citation 
Bronley-DeLancey, Apryl, "Effect of Genetic Variation on the Formation of Hepatocarcinogenic Metabolites 
of Trichloroethylene Using Chloral Hydrate Studies (an Interdisciplinary Approach)" (2005). MUSC Theses 
and Dissertations. 166. 
https://medica-musc.researchcommons.org/theses/166 
This Thesis is brought to you for free and open access by MEDICA. It has been accepted for inclusion in MUSC 
Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact 
medica@musc.edu. 
EFFECT OF GENETIC VARIATION ON THE FORMATION OF 
HEPATOCARCINOGENIC METABOLITES OF TRICHLOROETHYLENE USING 
CHLORAL HYDRATE STUDIES (AN INTERDISCIPLINARY APPROACH) 
By 
Apryl Bronley-DeLancey 
A thesis submitted to the faculty of the Medical University of South Carolina in partial 
fulfillment of the requirement for the degree of Master of Science in the College of 
Graduate Studies 
Department of Biostatistics, Bioinformatics, and Epidemiology 
Approved by: 
Table of Contents 
Ab 
... 
stract .............................................................................. 111 
Introduction .......................................................................... 1 
Literature Review ................................................................... 7 
Pharmacokinetics .................................................................................. 8 
Genetics ............................................................................................. 9 
QuantificationlRisk Assessment ................................................................ 10 
Materials and Methods ............................................................ 1 0 
Specific Aim 1 (Pharmacokinetics) ............................................................. 1 0 
Specific Aim 2 (Genetics) ........................................................................ 15 
Specific Aim 3 (Quantitative) ................................................................... 17 
Results ............................................................................... 19 
Discussion ........................................................................... 28 
References ........................................................................... 31 
Appendix A - Thiele Modulus ................................................... 35 
Appendix B - Lineweaver-Burke Plots .......................................... 36 
Appendix C - SAS Code .......................................................... 40 
Appendix D - Selected Stepwise Regression Results ......................... 44 
11 
Abstract 
Trichloroethylene (TCE) is listed with the EPA as a suspected human carcinogen and is 
ubiquitous in the environment (US EPA 1992). Chloral hydrate (CH) is a sedative drug 
and a cytochrome P450 (CYP 450)-derived metabolite ofTCE (Klaassen 2001). Chloral 
hydrate is metabolized in the liver to the rodent hepatocarcinogen trichloroacetate (TCA) 
by aldehyde dehydrogenase (ALDH), and to the non-carcinogenic metabolite 
trichloroethanol (TCEOH) by alcohol dehydrogenase (AD H) (Klaassen 2001). Both 
ALDH and ADH are polymorphic in humans which can presumably predict the 
disposition of chloral hydrate into the carcinogenic vs. non-carcinogenic pathways. The 
likelihood is then raised that subpopulations of humans will produce greater amounts of 
TCA relative to TCEOH and hence has greater risk of developing liver tumors after TCE 
exposure. To determine the variability of chloral hydrate metabolism in humans, the 
compound (0.05-2.0 mM) is added to human hepatocyte suspensions obtained from 
commercial sources. Incubations are carried out for 10 min at 37°C, with reactions 
stopped by the addition of an esterizer solution. The formation of TCA and TCEOH is 
then measured using headspace gas chromatography with electron-capture detection. The 
evolution of these metabolites was found to be highly variable with the Vmax means of 
f..LTCEOH = 26.32 ± 65.66 andJ-LrcA = 16.79 ± 44.94. Prior to determining human hepatocyte 
chloral hydrate metabolism, the inter- and intra-individual variability in metabolism of 
chloral hydrate was determined using rat and mouse liver homogenates from in-bred, 
genetically equivalent animals. Finally, the calculations are involved in predicting risk 
using the results of the pharmacokinetics and genetic typing. We believe that chloral 
hydrate metabolism will show variability among humans, exhibiting sensitive genotypes 
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that have specific kinetics which can be extrapolated to trichloroethylene sensitivity. A 
prudent approach to this problem merges pharmacology, genetics, and quantitative 
techniques. The best risk predictors for a high Vmax of both TCEOH and TCA 
metabolism is the ALDH2 genotype, followed by the ADH3 genotypes. We also suspect 
the ADH2 genotype would be an important covariate in the model; however none of our 
samples were of the atypical form. A more diverse and larger sample group would 
provide support of this study'S findings. Here we report a framework to determine risk 
which incorporates genetic typing. 
IV 
Introduction 
Trichloroethylene (TRIor TCE), a common metal degreasing solvent, is considered to be 
the major component in more than half of the EPA's hazardous waste sites (Klaassen 
2001). While TeE is not commonly considered to cause carcinogenicity in short-term 
exposures, its long-term effects have been disputed for decades (Lewandowski 2005). 
TCE is metabolized by CYP450 2E 1 to chloral hydrate. This first metabolite is a 
commonly used pediatric sedative and hypnotic. Following the formation of chloral 
hydrate, the compound is further metabolized by alcohol dehydrogenase (ALDH) to 
trichloroacetic acid (TCA) and by alcohol dehydrogenase (ADH) to trichloroethanol 
(TCEOH) (Figure 1). The formation ofTCA is suspected to be the source of 
carcinogenicity and those with a higher V max value of the toxin are thought to be at 
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Figure 1. Metabolism ofTCE to chloral hydrate and consequent disposition into carcinogenic (toxic) 
and non-carcinogenic (non-toxic) pathways. CYP2E 1 = cytochrome P450 isoform 2E 1; ALDH = aldehyde 
dehydrogenase; ADH = alcohol dehydrogenase; NAD = nicotinamide adenine dinucleotide, oxidized; 
NADH = nicotinamide adenine dinucleotide, reduced (McMillan 2004) 
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The EPA has listed TCE as an environmental hazard and states it is mostly released into 
the atmosphere from industrial degreasing operations (US EPA 1992). It is also reported 
by the agency as an acute central nervous system depressant that causes dizziness, 
headaches, confusion, euphoria, facial numbness, and weakness. Moreover, it is 
associated with several types of cancers in humans, particularly kidney, liver, cervix, and 
the lymphatic system. 
Furthermore, TCE has been shown to induce hepatic tumorgenesis in the B6C3Fl mouse 
but not in rats (Lipscomb 1996), where kidney tumors are produced. It is necessary to 
determine the risk to humans since over 200,000 pounds have been released into the 
environment from 1987-1993 alone (US EPA 1992). Should this compound be truly 
harmful to humans as described, mechanisms and funds to remove most of the compound 
from the environment are requisite. 
It is commonly accepted that the oxidative metabolites, particularly TCA, are responsible 
for the hepatocellular carcinoma in the B6C3F1 mouse (McMillan 2004b). TCA further 
dissociates or metabolizes to dichloracetic acid (DCA); which has only been recently 
shown to be a conclusive metabolic product and not an experimental procedural artifact 
(Delinsky 2005). This metabolite had been previously identified in vivo (Henderson 
1997) but was thought to be a by-product ofTCA formation rather than a metabolic 
product. Factors that influence either the rate or the extent of formation of these 
metabolites are of importance in regard to the reliability of risk estimates, especially in 
the recognition of subpopulations at greater risk (McMillan 2004). 
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It is known that a majority of individuals from Asian descent have a polymorphism in the 
ADH enzyme that causes an increased sensitivity to alcohol (Agarwal 1981) known as 
atypical ADH (ADH P2P2). This sensitivity results in a buildup of toxic metabolites that 
can cause a flush response (reddening of the skin). It is reasonable that these individuals 
would also have a particular sensitivity to trichloroethylene as the same enzymes are 
involved. Moreover, it has been reported that those with atypical ADH are usually 
deficient in ALDH2 (Yin 1984). The ADH polymorphism is caused by a single 
nucleotide substitution in codon 47 or codon 369, which results in an arginine to histidine 
or cysteine substitution, respectively (Tanaka 1996). Altogether, there are several ADH 
and ALDH isoforms (Table 1). 
ADHForm Subunits Isoforms 
ADH2 P}' P 2 PIP h P IP 2, P 2 P 2 
ADH3 "{I, "{2 "{I "{I, "{I "{2, "{2 "{2 
ALDHForm Subunits Polymorphisms 
ALDH homotetramer of 1*2,1*2 
54-kDa subunits 
Table 1 Isoforms and polymorphisms of the ADH and ALDH enzymes that are most important in chloral 
hydrate metabolism (Klaassen 2001, McMillan 2004) 
Although there have been several studies characterizing genes for AD H, the changing 
nomenclature over the years has made this a confusing undertaking (Table 2). Of the 
seven known human ADH-encoding genes, 4 are involved in the first step of ethanol 
metabolism (Osier 1999) and are presumably involved in the non-toxic pathway ofTCE 
metabolism. 
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PIfJl /31/32 fJ2fJ2 YIY1 Y2Y2 
ADH2*1 ADH2*1/ ADH2*2 ADH2*2 ADH3*1 ADH3*2 
ADHI I ADHI 
1 1 
ADHIIADH2 2 2 ADH2 / ADH2 2 2 ADHI I ADHl 3 3 ADH2~ I ADH2~ 
ADH2Bl AD H2 heterodimer ADH2B2 ADH3Yl ADH3Y2 
ADH2 isoform AD H2 isoform Atypical ADH ADH3 isoform ADH3 isoform 
Table 2 Different names used for the ADH isoforms, in addition the fJlfJ2 isoform has been identified as 
having fJ3 code for it which can confuse genotyping efforts further (Yin 1984, Burnell 1988, Ehrig 1990, 
Osier 1999, Borras 2000, Klaassen 2001, Mulligan 2003) 
Approximately 8% of the United States population has the ADH P2P2 genotype, not 
including Native Americans or those of mixed race (Yin 1984, US Census Bureau 2000). 
This translates to over 2,250,000 people according to the records from the 2000 Census. 
Using the kinetics of ethanol metabolism (Bosron 1993), it is possible to predict whether 
a random sample from our studies exhibits the atypical ADH P2P2 or the "normal" ADH 
~lPl since the identical enzymes are involved (Table 3) in chloral hydrate metabolism. A 
heterodimer, PIP2, is also possible but kinetics are only known for each subunit and not as 
a combination of the two (Bosron 1993). In the animal model it is reported that the 
species with the highest predisposition for liver tumors is the one which has the highest 
metabolic capacity for xenobiotics (Lipscomb 1996). This asserts that those isoforms 
with the higher Vmax values would then be more likely to develop hepatocarcinomas. 
Subunit fJIP1 fJ2P2 Y1Y1 Y2Y2 
Km 
mM 0.049 0.94 1 0.63 
Vmax 
per min 9.2 400 87 35 
(Yin & Burnell) 
Vmax 
per min 9 340 88 35 
(Osier) 
Table 3 Kinetic parameters of selected ADH isoforms from ethanol metabolism - this enzyme is 
involved in both ethanol and trichloroethylene metabolism. (Yin 1984, Burnell 1988, Osier 1999) 
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The use ofPBPK (physiologically-based pharmacokinetic) modeling of blood TeA 
levels as a dose metric for liver exposure to TeA after TeE ingestion is widely accepted 
(US EPA 2005). Unfortunately, the associations between TeE exposure and liver levels 
are complex and are very likely to show major differences among human subpopulations. 
These differences may underlie enhanced vulnerability or resistance by both genetic and 
environmental factors. The interface of the genetic and environmental pieces may further 
alter the relationship between applied dose of TeE and liver exposure to TeA (McMillan 
2004). The current PBPK model that is used for risk assessment (Figure 2) does not 
account for a genetic variability or sensitive subpopulations with respect to liver 
metabolism. The models fit an occupational or groundwater exposure situation. For 
example, the accepted occupational form is simulating a 70kg male for an 8 hour 
exposure. The groundwater model also assumes a 70kg male; hence variation in risk 
assessment models is necessary. There are many others that can easily be exposed to this 
ubiquitous environmental contaminant. 
To assess risk, the Vmax parameter is used as this measures the rate of the reaction of the 
enzynle involved. This research intends to provide a framework to assist risk assessment 
that the PBPK model does not generally cover. 
5 
Figure 2 Schematic representation of current PBPK model for TeE from an occupational inhalation 
exposure (Fisher 2000) 
The approach to this question will encompass pharmacology, genetics, and mathematical 
modeling to attempt to quantify risk. Established pharmacological methods to collect 
kinetic parameters using Lineweaver-Burke plots and Michaelis-Menten parameters are 
first employed. This is later modified through a quantitative approach by testing if a 
parameter to account for enzyme-substrate diffusion is necessary. Molecular biology is 
necessary to type the genetic profiles of the samples. Finally, representing the system 
with quantitative tools combined with the genetic and demographic information can be 
used to generate a valid prediction model. Much toxicokinetic research has relied on 
Michaelis-Menten kinetics without taking into account that metabolic systems do not 
always follow a linear equation. It has only been in recent years that computational 
technologies (i.e. faster computers, newer software versions like SAS and Matlab) have 
been able to handle systems that are non-linear in a timely fashion. Recording the kinetic 
measurements, typing the genetic isoforms, modifying metabolic equations, and 
modeling the final result can provide a valuable risk-assessment tool. 
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Currently, the National Institutes of Health Roadmap emphasizes the need for 
interdisciplinary research to remove roadblocks in new discoveries (US DHHS-NIH 
2003). The group of scientists researching the TCE issue has generally come from either 
a pharmacological or an epidemiological background. Up to this point, no one 
investigating the question of TCE toxicity has attempted to encompass the methods 
discussed here. 
Literature Review 
In order to review the literature for this research there are three main themes to review. 
Firstly is the historical perspective of the enzymes (ADH and ALDH). This is 
encompassed by the field of pharmacology, which has traditionally explained metabolism 
using the Michaelis-Menten equation. While this was an exceptional breakthrough when 
developed in 1913, technologies such as faster computers and software have evolved that 
can better describe enzyme kinetics. Performing a PubMed search for "Michaelis-
Menten" yields 5270 articles, including 83 are review articles, dating back to 1949. More 
modem considerations for describing metabolism, such as the Thiele modulus, bring up 
only 23 articles and typing in "metabolic modeling" only brings up 37 articles with 8 that 
are review articles. On the other hand, "mass transfer" shows 2328 articles, with 113 of 
those being review articles. Of course, the latter terms can be used as a different 
description than for biochemical engineering because when "mass transfer equations" are 
used in the search only 4 returns are available, none of which are review articles. The 
second consideration of this study deals with molecular biology techniques that have 
been well characterized. Third, the merging and quantification of the first two 
methodologies can be described as the risk assessment section. All of these disciplines 
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are used to describe the risk of trichloroethylene exposure. It can then be inferred that all 
three disciplines are encompassed by a larger description of epidemiology. These types 
of studies customarily describe the risk from exposures which are usually occupational 
exposures. A PubMed search for all three portions of the research, "risk assessment" + 
"trichloroethylene" + "genetics", only return 4 articles where 3 are review manuscripts. 
This is an interesting fact being that asking for "trichloroethylene" alone in PubMed 
returns 3412 articles, 206 of which are review. Additionally "risk assessment" provides 
60450, with 12429 as review documents (the similar "prediction model" search terms 
show 641, 24 are review). Searching for the term "genetics" alone was not attempted 
since the implication is extremely broad. 
Pharmacokinetics 
In the past, pharmacokinetic studies relied on more primitive methods for metabolism 
quantification. These methods included dosing rats with a desired compound and then 
homogenizing the whole animal to quantify metabolite formation (Creaven 1969). This 
practice is no longer in use and it is well-known that the body, human or otherwise, 
metabolizes substances differently in different organs and tissues. Still widely in use 
today, however, is the Michaelis-Menten equation (Equation 1) to describe metabolism. 
This equation is only valid if the enzyme follows first-order kinetics. 
(1) 
In this equation v = velocity or rate of the reaction, V max is the maximum velocity of the 
reaction, Km is the concentration at which Y2 of the active sites on the enzyme are 
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occupied and S is the substrate concentration (Stryer 1998). First order-kinetics then 
forms a linear plot when the reciprocal of V max is plotted against the reciprocal of Km. 
If the double reciprocal plot is not linear, there are other factors involved such as more 
than one enzyme is at work in the system or steric considerations. Biochemical 
engineering now takes into account other parameters in enzyme kinetics (Mardh 1986) 
but this is not always necessary. 
Genetics 
Most of the sensitive genotypes of ADH and ALDH have been identified by research 
groups in Asia. Researchers in the United States do not have as straightforward access to 
a pool of the atypical genotypes for these enzymes. In 1986 Duester et al reported 
molecular differences in the beta subunit encoding portion of the ADH gene and Haag et 
al reported nucleotide differences with the "(I and "(2 subunits. Later, in 1988 Xu et al 
reported PCR parameters to amplify the ADH2 and ADH3 genotypes. In 1993 
Nakamura et al further optimized the genetic typing of the ALDH2 isoform that is 
involved in atypical metabolism. This was accomplished by exploiting the fact that it is 
merely a one nucleotide substitution difference between the "normal" and the mutated 
enzyme. Through PCR and use of the MboII restriction-enzyme recognition site, genetic 
typing of the ALDH2 gene is easily carried out. From there, several researchers made 
use of this and other one-nucleotide substitutions for the ADH enzymes first reported by 
the Tanaka et al research on Japanese alcoholism in 1996 (Osier 1999, Borras 2000, 
Mulligan 2003). The methods of isolating DNA, using peR to amplify the gene of 
interest, and visualizing the results on a polyacrylamide gel are now commonplace and 
are typically complementary to a particular study, as in this case. 
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There are a number of modem tools that provide ease of use for these types of 
experiments to supplement a study, including tutorials and user-friendly formats. For 
example, NCBI's website portal for BLASTn (Basic Local Alignment Search Tool-
nucleotide at bttp://www.ncbi.nlm.nib.govIBLAST) has several algorithms in place to 
easily align and locate sequences (for example: Dowd 2005, Yang 2002). Additionally 
New England Biolabs has a web portal (http://rebase.neb.com/rebase/rebase.html) that 
will match restriction enzymes to the sequences of interest (Roberts 2005). 
QuantificationlRisk Assessment 
This perhaps the most important part of the current study in that it unifies all disciplines 
used. For TCE risk assessment, PBPK modeling has been used for occupational and 
groundwater exposures (Fisher 2000). Current models for TCE exposure risk make no 
mention of sensitive subpopulations or varied genetics (NIEHS 2000, US EPA 2001) and 
simulate exposures for 70 kg males. There have been many environmental releases of 
TCE, therefore exposing it to the general population. No current model ofTCE risk 
accounts for genotype of the ALDH or ADH enzymes in any way. 
Materials and Methods 
To incorporate the three methodologies of this study, the methods have been 
differentiated into three specific aims to address each contributing methodology. 
Specific Aim 1: (Pharmacokinetics) to determine variability in the kinetics of 
formation of the chloral hydrate (a first-pass metabolite of TCE) metabolites, TeA 
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and TCEOH using primary human hepatocyte cultures. Within this, experimental 
model validation is needed: 
a. To validate assay with rat model for intra-individual variability. 
b. To validate assay with mouse model for inter-individual (with same 
genetic profile) variability. 
Experimental: 
Assay Validity: To rule out the possibility of procedural error, one liver from a male 
Sprague-Dawley rat was divided into 5 portions and subject to homogenization and 
incubation. Each aliquot was incubated with chloral hydrate and 0.9 mM of cofactor 
(NADINADP) is added to each reaction vial. It was found in a previous study (Lipscomb 
1999) that this is the most favorable amount of cofactor for this reaction. 
These values were used to validate the human data collected. This was necessary to 
remove the question of variability in these samples being from anything but genetic 
makeup or environmental factors; not procedural handling. It was determined that 5 
aliquots would be sufficient as it is standard biological practice to validate with at least 3-
4 replications. An n = 5 or less has been used in previous studies of this type for method 
validity (Lipscomb 1998, Delinsky 2005) and has been determined acceptable in the lab. 
Additionally, livers from four male B6C3F 1 mice of approximately the same age and 
weight were homogenized and subj ected to the same chloral hydrate and cofactor 
treatment. All have Km, Vmax and first-order rate constants collected in the same 
manner as the hepatocyte treatment. 
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Hepatocytes: Human cryopreserved hepatocytes were purchased from InVitro 
Technologies (IVT; Baltimore, MD) and ZenBio (Research Triangle, NC). The donors 
are selected randomly, either by what becomes available through email communication 
from the merchant or from arbitrary selection of the supplier. The hepatocytes were 
thawed and unpacked according to instructions (InVitro Technologies) and then counted 
with cell viability verified by trypan-blue exclusion method. Hepatocytes were then 
diluted to a concentration of lxl06 cells/mL with IVT HI Incubation Medium and 
transferred to reaction vials. Should this cell concentration not be attainable in the 
particular incubation, the exact amount is noted and converted to lxl06 cells/mL. This 
value was chosen for simplicity in later calculations. Chloral hydrate was added 
(0.01 JlM-2JlM) to each vial and allowed to incubate with gentle shaking for 10 minutes at 
37°C. A 10JlL sample was then withdrawn from each vial and placed in a 20mL GC vial 
(Perkin-Elmer Boston MA) with 200JlL esterizer already in place. The esterizer 
(Muralidahara 1999) enables volatilization of the acetates in the sample. These samples 
were then analyzed for metabolites. 
GC Analysis: Gas Chromatography is performed by the method Muralidhara and 
Bruckner (Muralidhara 1999). Samples were analyzed using a Perkin Elmer Autosystem 
XL gas chromatograph fitted with a headspace sampler and electron-capture detector 
(ECD), equipped with a 10'xl/8" OD stainless steel column. The column is packed with 
10% OV -17 on Supelcoport (Supelco). The ECD method of detection has been shown to 
reliably detect halogenated compounds (Lipscomb 1996, Jiang 2004). Additionally, the 
preferred method of detecting TCE metabolites is via GC-ECD (ASTDR 1997). All GC 
vials have an esterification (esterizer) blend added prior to the addition of biological 
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samples. This blend is 6 parts de-ionized water, 5 parts sulfuric acid (Fisher Scientific, 
Fairlawn NJ), and 1 part methanol (Fisher Scientific). The water and sulfuric acid 
mixture should be prepared first and allowed to cool before addition of methanol. The 
esterizer allows volatilization of some of the metabolites for analysis by GC. In GC 
analysis, it is necessary to have the analyte in gaseous form. Analytes that cannot be 
volatilized into the gas phase cannot be detected. To determine amount of metabolite 
formation, a standard curve is used. This standards consist of 10 samples with 10-1 OOOng 
of DCA, TCEOH, and TCA to be run on the GC prior to loading the unknowns. The 
settings on the GC are as follows: needle = 110°C, transfer line = 120°C, oven = 130°C 
for the autosampler and headspace unit. The samples pressurize for 1.0 min, inject for 
0.08 min, withdraw for 0.4 min, and have the therm time at 30 minutes. The GC part of 
the machine has an isothermal column at 150°C, the injector at 200°C, and the detector at 
360°C. Nitrogen is used as the carrier gas, with the psi set to 20.0 on the headspace unit. 
Km and Vmax Calculations: Of interest are the kinetic parameters Km, Vmax, and 
VmaxlKm (the rate constant). A standard curve with concentrations of 10-1000ng of 
metabolites was generated using by gas chromatography analysis as described. A 
regression line was fit for GC peak response vs. ng of analyte (In the form y = mx +b). 
The response values of the biological samples were then substituted for the x value in the 
previous equation and further transformed by multiplying by molecular weight of analyte. 
The reciprocal of the obtained value was then plotted against the reciprocal of the 
corresponding CH concentrations (Lineweaver-Burke plot). A regression line was again 
fit. From the final model in the form y = mx + b, b is equal to the reciprocal of V max 
and Km is equal to the negative reciprocal of (y-b )/m as in traditional Lineweaver-Burke 
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plotting (Figure 3). For each sample, whether hepatocyte mixture or liver homogenate, 
the Km and Vmax parameters are normalized to 1 x 106 cells using the parameters from 
table 18 of Lash et. ale (Table 4) (Lash 2000). The assumption is made with these data 
that microsomal protein data (originally reported in the reference) may be extrapolated to 
use as whole cell or whole homogenate as well. 
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Figure 3 Lineweaver-Burke Plot for one donor cell incubation experiment 
Parameter Value 
Human Hepatocyte Density 116 xI 06 cells/ g liver 
Protein density: whole liver 20.88 mg proteinlg liver 
Protein density: isolated cells 179 Jlg proteinll06 cells 
Table 4 Conversions for cells and tissue to use with transforming kinetic parameters (Lash 2000) 
Variability Analysis: Raw data used to construct the Lineweaver-Burke plot was then 
entered into Stata 8.2 and robust regressions are performed to remove outliers. Each set 
of observations has had the baseline values subtracted for accuracy. Using the "rreg" 
command in Stata the program goes through Huber and Biweight iterations until 
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convergence to fit the regression model. The final kinetic values are determined using 
this method. Appendix B shows the initial Lineweaver-Burke plots with only baseline 
correction made using the ordinary least squares method. The HL6, AOK, and KTG cells 
had values that differed greatly when using robust methods. SAS © 9.0 is used to 
determine mean, median, and standard deviation of the samples with the "proc 
univariate" command. 
Specific Aim 2: (Genetics) to determine the relationship between the kinetics of 
metabolite formation and hepatic ADH and ALDH genotypes. 
Experimental: 
Genotyping: Analysis of the ADH2, ADH3, and ALDH2 isoforms was performed 
according to previously described methods (Nakamura 1993). The first procedure 
necessary was to isolate the DNA from the samples, cleanly done via the commercially 
available Qiagen DNeasy Tissue Kit with the optional RNase A step included (Qiagen 
Inc. Valencia, CA). Once isolated, PCR amplification of the ADH and ALDH alleles 
was accomplished. This procedure was done by first preparing the mixture with the 
corresponding primers. Primers were obtained through Integrated DNA 
Technologies (IDT, Coralville IA) and have been previously characterized (Yin 1984, 
Burnell 1988, Ehrig 1990, Osier 1999, Klaassen 2001, Mulligan 2003) (Table 5). 
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Isoform 
Primer Sequence for Genotyping 
Restriction 
(primer id) Enzyme 
ALDH2 (YC3) 5'- TTG GTG GCT AGA AGA TGT C- 3' MboII 
ALDH2 (YC4) 5'- CCA CAe TCA CAG TTT TCT CTT - 3' MboII 
ADH2 (A2F) 5'- ATT CTA AAT TGT TTA ATT CAA GAA G - 3' MslI 
ADH2 (A2R) 5'- ACT AAC ACA GAA TTA CTG GAC - 3' MslI 
ADH2 (424) 5' - TGG ACT CTC ACA ACA AGC ATG GT - 3' AluI 
ADH2 (290) 5' - TTT CTT TGG AAA GCC CCC AT - 3' Alul 
ADH2 (352) 5'- TCT TTC CTA TTG CAG TAG C -3' AluI 
ADH3 (321) 5' - GCT TTA AGA GTA AAT ATT CTG TCC CC - 3' Sspl 
ADH3 (351) 5' - AAT CTA CCT CTT TCC GAA GC - 3' Sspl 
Table 5 Primer sequences used in determining isoforms of interest ALDH and ADH 
Each 0.5 JlL micro-centrifuge genotyping reaction tube contained: 20 JlL EppendorfHot 
Master Mix (Fisher), 1 JlL of 5JlM Forward primer (IDT), 1 JlL of 5JlM Reverse primer 
(IDT), 17 JlL Sterile water, 10 JlL isolated DNA template. Each tube was then subject 
to PCR under these conditions: 4 minutes at 95° C, 1 minute at 95 ° C, 1 minute at 55 ° 
C, 1 minute at 72 ° C, then the 2nd _4th steps cycled 34 times, 30 minutes at 72 ° C, and 
finally hold at 4 ° C. Next, PCR product was isolated from the whole DNA by restriction 
enzyme digest. The restriction enzymes needed are commercially available along with 
corresponding buffers (New England Biolabs, Beverly, MA)o For the genotypes used the 
restriction enzymes are: ADH2 = MslI and Alu I, ADH3 = Ssp I, and ALDH2 = Mbo II. 
To the isolated product, the corresponding enzyme and buffer were added with 005 JlL 
BSA (Promega Madison, WI) to digest 2-3 hours at 37°Co The recipe for each tube was: 
PCR Product = 20 JlL, H20 (RNase, DNase Free) = 50S JlL, Buffer::::: 3 JlL, Enzyme = 1 
JlL, BSA = 0.5 JlL. To analyze the product, 10% TBE Novex Gel (Invitrogen Carlsbad, 
CA) was loaded with 10 JlL of digestion product with 2 JlL Hi-Density sample buffer 
(Invitrogen). A 100-bp DNA ladder was used to determine product molecular weight 
along with the colors of the running buffer as it separates and the xylene band will end at 
120 bp and the bromophenol band stops at 35 bp. The gel was run at 200V for 20 
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minutes. Gels were stained in 50 mL de-ionized water with 5JlL ethidium bromide 
(Fisher) for 20 minutes then de-stained with de-ionized water for 20 minutes. The gels 
were photographed using Biorad Quantity One ChemDoc software. Atypical ALDH2 
was determined when more than one band appeared on the gel, since the "normal" 
enzyme would only yield a 91 bp band. For the ADH2 ~2 gels, the presence of2 bands 
near 50bp established that there was not the "atypical" form that is normally seen in 
Asian populations (Figure 4). To determine the ADH2 type, a separate gel that had 
products in either 180 or 232 bp (or both) was compared to known controls to determine 
genotype. Finally for the ADH3 genotype the appearance/absence of a band at 145 bp 
with comparison to known controls was used. 
Figure 4. Bands for "normal" ADH2 genotype, the atypical genotype would be and absence of the 
two band pattern below the 100bp mark (not visible in this representative gel) 
Specific Aim 3: (Quantitative) to generate valid tools to incorporate/make 
inferences to the degree of human variability in metabolite formation into a 
regression model using demographic, genetic, and metabolic covariates 
Experimental: 
To effectively model the metabolic parameters it was first thought that mass transfer 
considerations to modify the rate constant (V maxlKm) would be a viable explanation. 
U sing the Thiele modulus can correct for this phenomena (Blanch 1997), taking into 
account the diffusivity of the particle through the enzyme (Appendix A). The physical 
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parameters can be estimated from existing literature (Mardh 1986). Traditionally, the 
Michaelis-Menten equation has not been subj ect to a correction factor to describe this 
metabolic system with TCE. It is reasonable to assume these mass transfer 
considerations depending on the experimental method. In a biologic system, there are 
indeed many factors that affect the workings of enzyme activity. The Thiele modulus 
was a preliminary attempt to control for other factors involved and has been described in 
biochemical engineering textbooks as a valid method (Blanch 1997). After consideration 
of the Lineweaver-Burke plots generated, it was deemed unnecessary to include a 
correction factor for the diffusivity and porosity of the particle and the enzyme. 
It became clear that the only necessary correction was to subtract the baseline activity 
from the final calculations. These values were subtracted in the MS Excel 2003 
algorithm that generated the Vmax points on the Lineweaver-Burke plots. The values 
from the standard curve are rearranged to solve for x, then multiplied by the volume of 
the reaction vessel and divided by the molecular weight. This is then divided by 10 to get 
a value per minute. After this, the robust regressions performed in Stata were 
recalculated. 
To visualize the clustering of the collected kinetic parameters, a log-log plot of the Vmax 
vs. the K.m was generated in MS Excel 2003. The log conversion was made in order to 
visualize all donors on one plot as the EJR donor had a V max that was substantially 
higher than the others. This plot was then coded to reflect donors with atypical ALDH2 
and illustrates the involvement with TCEOH formation by this enzyme. 
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To assess risk the Vmax of the enzymes are used by convention (Lipscomb 2003, Yin 
1984). This parameter is chosen as the standard being that is the asymptotic value of the 
dependence of the reaction rate as a function of concentration and can be estimated by 
generic formulas. The other widely-used parameter generated from the Lineweaver-
Burke plot, Km, is much less precise since it is the concentration for half saturation 
kinetics and relies on an accurate description of rate as a function of concentration. 
To make inferences, a model selecting relevant covariates of age, sex, race, alcohol use, 
and genotype with robust selection and outlier diagnostics is fit using SAS © 9.0 
(Appendix C). High risk is described as a high Vmax value, close to 100 units per time, 
as this is modified from the known value for the atypical genotype for ADH2 (Table 3). 
F or the purposes of this study, we will characterize those with a V max over 100 
nmoles/minll06 cells as high risk and those under as low risk. For values close to the 
cutoff, other considerations should be used to infer risk such as genotype, alcohol use, or 
other demographic parameters. 
Results 
With a working assay in place (Table 4 and Table 5) it is possible to substitute human 
characterization studies for further animal testing. Well-refined and well-characterized in 
vitro systems can reduce the dependence on animal and human testing. The quality and 
availability of human hepatocytes has greatly improved, and these have been shown to 
imitate qualitatively the metabolic products of the intact liver (Billings 1997, Bosron 
1993). 
19 
All results of the rat and mouse model studies were within acceptable standard 
deviations. Additional validation studies were performed (data not shown) using Cac02 
cells as a negative control. These cells presumably have limited ADH and ALDH and the 
incubationlGC experiments concurred that there was nearly no activity. A Lineweaver-
Burke plot of the data revealed a virtually flat response. 
Summary Statistics - SD Rat Experimental Validation 
Km=mM 
Vmax = nmoles/mg protein/minute 
Parameter Mean Median Standard 
Deviation 
Km TCEOH 0.010 0.010 ±0.0098 
KmTCA 0.002 0.002 ±0.0003 
VmaxTCEOH 0.393 0.443 ±O.l360 
VmaxTCA 0.168 0.163 ±0.0225 
Table 4 Summary statistics for five aliquots of the same male Sprague-Dawley rat liver 
Experiment Date TCEOH VmaxlKm TCA VmaxlKm 
03/21/05 0.09 0.07 
04/21/05 0.07 0.08 
04/22/05 0.07 0.07 
Standard Deviation ±0.009 ±0.007 
Table 5 Summary for genetically similar individual male B6 mouse validation experiments 
Other comparisons were made between the same donor cells in different formats. One 
donor was incubated as cryopreserved & thawed vs. plated. The plated cells were also 
compared to one another with incubations from each successive passage. Another set of 
experiments was performed as cryopreserved vs. liver homogenate (data not shown). All 
three revealed different kinetic parameters between formats. The cryopreserved cells had 
higher kinetic values than the plated cells or the liver homogenate. TCEOH formation 
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was not detectable in the homogenate but TCA was quantifiable. Also, parameters 
changed with each cell culture passage (Table 6). 
Format! TCEOH TCEOH TCEOH TCA TCA TCA TCA Rate/ 
Passage Km Vmax Rate Km Vmax Rate TCEOH 
Rate 
Cryopreserved 0.0430 0.5900 13.72 0.0050 1.2000 240.00 17.49 
Plated 0.0230 0.3170 13.78 0.0030 0.5370 179.00 12.99 
Primary 
I 0.0140 0.6500 46.43 0.0004 0.5910 1477.50 31.82 
2 0.0146 0.1185 8.13 0.0004 0.1416 333.28 40.99 
3 0.0156 0.1250 8.00 0.0021 0.0764 35.71 4.46 
4 0.2030 0.1209 0.60 0.0001 0.0647 726.00 1219.52 
Table 6. Summary ofKm, Vmax, VmaxIKm (Rate) and ratio of rates for the same donor cells incubated 
at different stages of cell culture. Note the rate constant does not remain the same. 
It was also determined that each incubation must be immediately analyzed on the GC, as 
freezing in a -20°C freezer does not preserve activity. The longer the incubated samples 






Table 7 Summary statistics of all 13 donor cells 




Human hepatocyte data has been collected in order to determine kinetic parameters. 
These data exhibited a wide variability evident from the mean's distance from the median 
(Table 7). Isolated human hepatocytes were treated according to the methods. The 
Vmax was collected for 13 humans selected at random. All demographic data available 
was also collected from the supplier in each case (Table 8). These data were then merged 
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with the experimentally collected genotypes. From all of these data the models were fit 
in order to make risk assessment inferences. 
Cells Viability 
Age 
Sex Race Tobacco Alcohol Substance 
TCEOH 
(years) Vmax 
AOK 73 47 M C y N N 
3.34 
CEC 86 48 M C Y Y Y 
4.42 
DAD 77 62 M C Y Y N 
1.45 
IOE 83 79 M C Y Y N 
6.99 
KTG 94 59 M C y y N 
33.33 
ZAG 85 59 M C y y N 
2.22 
CHD 77 72 F AA N N N 
2.36 
EJR 75 56 F C N N N 
222.22 
HL10 80 42 M AA Y Y Y 
12.07 
HL6 98 48 F C N N N 
0.54 
HL7 98 55 F C N N N 
ND 
HL8 98 56 M C Y Y N 
ND 
HL12 76 0.03 F C N N N 
0.59 
Table 8 Demographics and Vmax values for donor cells/tissue: ND = no linear portion could be fit 
through traditional or robust methods, substance for CEC cells = marijuana, 

















Cells TCEOH TCA ALDH2 ADH2 ADH3 
Vrnax Vrnax Type Type Type 
AOK 3.34 16.94 Atypical PIPI Y1Y2 
CEC 4.42 4.59 2*1 Homo PIPI YIY2 
DAD 1.45 0.71 2*1 Homo PIP2 Y1Y1 
IOE 6.99 6.76 2*1 Homo PI PI Y.Y. 
KTG 33.33 4.15 2*1 Homo PI PI Y.Y1 
ZAG 2.22 2.28 2*1 Homo PIP2 YIYI 
CHD 2.36 1.22 2*1 Homo PI PI Y.Y2 
EJR 222.22 158.73 Atypical PIP2 YIY2 
HLI0 12.07 4.35 2*1 Homo PI PI Y1YI 
HL6 0.54 ND 2*1 Homo PI PI YIY2 
HL7 ND 0.14 2*1 Homo PI PI Y.YI 
HL8 ND 0.41 2*1 Homo PIP2 YIYI 
HL12 0.59 1.20 2*1 Homo PI PI Y2Y2 
Table 9 Kinetics and genotypes of cells - the predictions are based solely on the rate constants and their 
similarity to those in Table 4. ND = no linear portion could be fit through traditional or robust methods, 
Atypical = that which is not ALDH2 * 1 
The only atypical genetics observed were from the ALDH2 gene (Table 9, Figure 5). It 
was presumed that there would not be many atypical individuals as the donors were 
mostly Caucasian. The sample set was this way due to the commercial sources having 
hepatocytes available from mostly Caucasian individuals. 
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+-100 bp 
(-) ZAG HLIO KTG AOK marker 
Figure 5 Gel of ALDH2 genotyping result for 4 donor cell DNA 
In order to empirically determine the clustering of the kinetics, the log-log plot of the 
Vmax vs. Km with atypical ALDH2 was generated (Figure 6). From this plot, the EJR 
donor with the highest Vmax value is clearly outside of the clustering of the other donors. 
The AOK donor cells were not expected to have an atypical genotype. The only 
similarity between the two donors is that they did not consume alcohol and they were 
both diabetic. This supports the genetic findings as they likely had adverse reactions to 
alcoholic beverages. Being only 47 years old, AOK was one of the youngest donors. 
Additionally, this Caucasian male suffered from non-insulin dependent diabetes and used 
tobacco. The EJR donor was a female Caucasian who did not use tobacco and was 56 
years old. Interestingly, she also suffered from diabetes but it is not known whether it 








































Figure 6 Log(Vmax) vs. Log(Km) plot for donors with respect to TCEOH metabolism - log scale used 
to view all on same plot and identify clusters or similarities 
Examining the TCA log-log plot also reveals the EJR as far away from the other with the 
AOK also at a distance from the others (Figure 7). In this plot, the donors are more 
clustered together than the TCEOH. Also of note is that in both plots, cells that were 
grown in cell culture plates are on the outer edges of the clusters (HL6, HL 7, and HLS). 
This could suggest an inherent difference in the cell format. The HL 12 cells were 
incubated as both a suspension from cryopreserved cells and as a suspension from cells in 
culture. The cultured cells had decreased Km, Vmax, and rate values from the 


































Figure 7 Log(Vmax) vs. Log(Km) plot for donors with respect to TeA metabolism -log scale used to 
view all on same plot and identify clusters or similarities 
Using stepwise regression (Appendix D), the most significant models to predict Vmax for 
both TCA and TCEOH were with ALDH2 as the only covariate (p = 0.0061 and p = 0.03, 
respectively). 
For visualization, plots of the Km, Vmax, and rate constant ofTCA vs. TCEOH show 
interesting points (Figures 8, 9, 10). First, while the Vmax plot seems to have a certain 
amount of linearity, the Km plot is randomly scattered. The rate constant plots show that 
the individuals are clustered together with the exception of EIR. This individual is again 
set apart. Also, the HL 12 cells are slightly away from the cluster. Again, these points are 
not unusual as EJR had a very high Vmax for both metabolites and was exceptional in 
other plots. HL 12 was also exceptional in some cases and this is most likely due to the 
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Figure 8 Log-Log plot ofVmax TCA vs. Vmax TCEOH 
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Figure 9 Log-Log plot of the rate constants TCA vs. TCEOH 
Discussion 
Of our thirteen samples, only two exhibited any genetic anomalies and only one of those 
is considered a high risk according to the high V max. Both samples came from diabetic 
donors suggesting this may be a necessary parameter in the prediction model. The only 
other known diabetic in the samples was the HL6 donor with non-insulin dependent 
diabetes. Incidentally, the log-log plot revealed this individual was outside of the main 
cluster of data but she did not have the atypical genotype. The other visual outlier of the 
plot was HL12 from an II-day old female. All but AOK are female that have these 
unique observations and none consumed alcohol. 
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The Km is not as useful for this study since this is mostly used as a partition coefficient 
for modeling the entire body with a PBPK model (Lipscomb 1998 & 2003, Kedderis 
2001). Additionally, the Km is most important when dealing with blood concentrations 
and blood flow to the liver. For this scenario, concentrations above the Km value are at 
saturation and then the risk of an individual doubles with the doubling of a Vmax value. 
The Km can be defined as the substrate concentration that gives Y2 the Vmax (Kedderis 
2001). Therefore, if the concentrations of the chemical or toxin are well below Km, the 
V max is not as useful. 
Using the pseudo first-order rate constant VmaxlKm is helpful for modeling risk in the 
entire body as in a PBPK model or when using more than one chemical. Using this rate 
is not as practical for this study as the experiments are performed in whole cells and not 
in a liver with blood flow to deliver of the compound of interest. 
U sing genetic information for an individual is not likely to be the sole decisive predictor 
of risk with respect to chloral hydrate or trichloroethylene sensitivity. Other research has 
looked at liver enzymes as predictors of kinetics, finding that even the same genotypes 
can vary widely in Vmax (Taguchi 2005). This study suggests that other health 
parameters such as diabetes may be necessary to consider. Most of the hepatocytes 
obtained are from donors whose livers were not suitable for transplant. Many times this 
is due to the donor having a fatty liver. Obtaining the desired human donor demographic 
can therefore be challenging. A great many of the donors are Caucasian and it is not 
discemable whether any of these individuals are of mixed race. Besides the known Asian 
background abnormality, Native American populations may also have a large majority 
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with atypical ADH (or a similar deficiency) (Mulligan 2003). These specifics add 
complexity to the issue of sensitive subpopulations. 
Additionally, bias may exist in the human samples. There is no easy way to account for 
any difference in the type of individual who agrees to donate organs and one who does 
not. It is doubtful that this will contribute much to the study results. What may 
contribute to the results is the matter that many of the donors either have a high body 
mass index or use alcohol on a regular basis. The effect of ethanol on TCE metabolism is 
not well known (McMillan 2004) and requires further investigation. 
In the future, it is necessary to further characterize genetic studies due to the number of 
isoforms and genes involved with TCE and chloral hydrate metabolism. Many in the 
United States population are heterozygotes for the ADH2 ~1 and ~2 alleles (Borras 2000), 
making characterization of gene expression with a particular metabolic rate for this 
genotype difficult. If the race of the donor is known, it is possible to speculate that a 
certain genotype will be represented or at least the chance will be greater. Again, most 
commercially available cryopreserved hepatocytes in the United States come from 
Caucasian donors with a few African-American donors and a very small portion of 
Hispanic donors. 
Future studies should further examine other health effects and increase the sample size of 
each genotype. The results presented here suggest diabetes may be a covariate worth 
examining in the risk model. Additionally, sample size optimization is necessary. To 
decipher sample size, it is necessary to find usable statistics on population variation. 
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Appendix A Thiele Modulus for mass transfer considerations 
R V max 
[ )
112 
t/J = 3 [Km][ Deff ] 
R V 
Where - = ---E... 
3 Sx 
Vp = the gross volume of the substrate particle 
Sx = the gross exterior surface area of the enzyme 
Ds = bulk diffusivity 
Gp = porosity of the particle 


































Appendix B Lineweaver-Burke Plots with raw data corrected for background 
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Appendix B Lineweaver-Burke Plots with raw data corrected for background 
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Appendix C SAS code to generate prediction model 
dm log "clea r "; 
dm output "clear' ''; 
options formdlim "nodate pageno 1 ; 
data tce; 
input ID$ viability age sex race tobacco alcohol substance tceoh tca ALDH2 ADH2 ADH31 ADH32 tceohr tcar ratio; 
/*SEX : male 0 , f.emale .L RACF: : 0 Caucas ian 3. Af.rica n :i'l.melica!1 
/ "T0BACCC. USE yes 1. , no ",,0 fo .. r..COHOl, US E 1 '1':'$ , () no 
/*5UBSTANCE (i ll icit d rug use) yes 1, no = 0 
/*A.T.,mr:.! () "" typica l .1 "" at.ypi.cal 
/"ADH2 1. '" heterodi.mer. 0 '" :n.ouiodi. u,e r: 
I*ADH3.l.l. gammal gam.mal. 0 o t;.bend.se 
;"ADH32 1 "" gdllulld2 gdllllua2 0 "" othc r wi:5c 
cards ; 
INSERT DATA HERE 
run; 
proc reg data = tce; 
.• I , 
I , 
.J.: / i 
.• J . 
I , 
.. / ; 
*/ i 
*/ i 
* / ; 
model tca = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/ r p cl.b clm cli collin vif ; 
plot 1'. *p . ; 
run; 
quit; 
pl ot r . *h . ; 
proc reg data = tce; 
model tca = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/ influence ; 
out put out = one residual=resid cookd=cookd h=hat dffits=dffits covrati.o=covrat press=press rstudent=rstu; 
run; 
quit; 
proc print data = one; 
var resid cookd hat dffits covrat press rstu; 
run; 
proc reg data = tce; 
model tca = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/influence ; 
output out = two residual=resid cookd=cookd h=hat dffits=dffits covratio=covrat press=press rstudent=rstu; 
run; 
quit; 
proc print data = two; 
var resid cookd hat dffits covrat press rstu; 
run; 
proc reg data = tce; 
model tceoh = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/r p clb elm cli collin vif ; 
plot r. *p. ; 
run; 
quit; 
plot r . *h . ; 
proc reg da t a = tce; 
model tceoh = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/in fluence ; 
output out = three residual=resid cookd=cookd h=hat dffits=dffits covratio=covrat press=press rstudent=rstu; 
run; 
quit; 
proc print data = three; 
var resid cookd hat dffits covrat press rstu; 
run; 
proc reg data = tce; 
model tceoh = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/influence ; 
output out = four residual=resid cookd=cookd h=hat dffits=dffits covratio=covrat press=press rstudent=rstu; 
run; 
quit; 
proc print data = four; 
var resid cookd hat dffits covrat press rstu; 
run; 
proc princomp data = tce; 
var age viability sex race tobacco alcohol SUbstance ALDH2 ADH2 ADH31 ADH32; 
run; 
proc corr data = tce; 
var age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32; 
run; 
proc reg data = tce; 
model tceoh '" age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/ selection cp ; 
run; 
quit; 
proc reg data = tce; 
run; 
quit; 
model tceoh = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/ selection 
proc reg data = tce; 
stepwise; 
model tca = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/selection cp ; 
run; 
quit; 
proc reg data = tce; 





proc reg data = tce; 
model tca = age viability sex race tobacco alcohol sUbstance ALDH2 ADH2 ADH31 ADH32/s election 
run; 
quit; 
proc reg data = tce; 
model tca = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
model tceoh = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
model tceoh = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
model tca = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
model tceoh = age viability sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 




proc reg data = tce; 




proc reg data = tce; 




proc reg data = tce; 




proc reg data = tce; 




proc reg data = tce; 




proc reg data = tce; 
run; 
quit; 
model tca = age sex race alcohol ALDH2/vif ; 
proc reg data = tce; 
run; 
quit; 
model tceoh = age sex race alcohol ALDH2/vif ; 
proc reg data = tce; 
run; 
qUit; 
model tca = age sex race ALDH2/vif ; 
proc reg data = tce; 
run; 
quit; 
model tceoh = age sex race ALDH2/ vif ; 
proc reg data = tce; 
run; 
quit; 
model tca = age sex race/vif ; 
proc reg data = tce; 
run; 
quit; 
model tceoh = age sex race/vif ; 










model tca age race/ vi t i 
proc reg data = tce; 
run; 
quit; 
model tceoh = age race/vif ; 
proc reg data = tce; 
model tca = age sex race alcohol substance ALDH2/ r p clb clm cli collin vif ; 
run; 
quit; 
proc reg data = tce; 





agesq = age*age; 
run; 
proc reg data = tce; 
model tca = agesq race alcohol ALDH2/ r p clb clm c l i col linoint vit i 
run; 
quit; 
proc univariate data tce; 
val:' tca tceoh; 
run; 
proc glm data = tce; 
run; 
quit; 
model tca = viability age sex substance ALDH2 ADH2 ADH31 ADH32; 
proc reg data = tce; 
run; 
quit; 
model tca = age sex race tobacco alcohol sUbstance/sel ection 
proc reg data = tce; 
run; 
quit; 
model tceoh = age sex race tobacco alcohol sUbstance/se lec t i on 
proc reg data = tce; 
run; 
quit; 
model tca = age sex race tobacco alcohol substance/ se l ect i on 
proc reg data = tce; 
run; 
quit; 
model tceoh = age sex race tobacco alcohol substance/ se l ec tion 
proc reg data = tce; 
run; 
quit; 
model tca = age sex race tobacco alcohol substance/ se l ect i on 
proc reg data = tce; 
run; 
quit; 







/" st.epwise rem('vin,] gene t.ype~; one at. (l t.ime i\n rat.io of r ates dnd r at.e,, " ; ; 
proc reg data = tce; 
model ratio = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH3 2/ selection stepwise; 
run; 
quit; 
proc reg data = tce; 
rnodel tceohr = viability age sex race tobacco alcohol sUbstance ALDH2 ADH2 ADH31 ADH32/ se l ection stepwise; 
run; 
quit; 
proc reg data = tce; 
model tcar = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection stepwise; 
run; 
quit ; 
proc reg data = tce; 
model ratio = viability age sex race tobacco alcohol substance ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg da t a = t ce; 
model tceohr = viability age sex race tobacco alcohol substance ADH2 ADH31 ADH32/ se l ection 
run; 
quit; 
proc reg data = tce; 







proc reg data = tce; 
model ratio = viability age sex race tobacco alcohol substance ADH2/ se l ect i on stepwise; 
run; 
quit; 
proc reg data = tce; 
model tceohr = viability age sex race tobacco alcohol substance ADH2/ selection stepwise; 
run ; 
quit; 
proc reg data = tce; 
model tcar = viability age sex race tobacco alcohol substance ADH2/ se l ec t ion stepwise; 
run; 
quit; 
proc reg data = tce; 
run; 
quit; 
model ratio = viability age sex race tobacco alcohol sUbstance/ se l ecti on 
proc reg data = tce; 
run; 
quit; 
model tceohr = viabi lity age sex race tobacco alcohol SUbstance/ se l ection 
proc reg data = tce; 
run; 
quit; 
model tcar = viability age sex race tobacco alcohol substance/ se l ect i on 




model tceoh = viabili t y age sex race tobacco alcohol substance ALDH2 ADH2 ADH3l ADH32/ se l ection stepwise; 
run; 
quit; 
proc reg data = tce; 
model tca = viability age sex race tobacco alcohol substance ALDH2 ADH2 ADH31 ADH32/ selection stepwise; 
run; 
quit; 
proc reg data = tce; 
model tceoh = viabili t y age sex race tobacco alcohol substance ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
rnodel tca = viability age sex race tobacco alcohol substance ADH2 ADH31 ADH32/ selection 
run; 
quit; 
proc reg data = tce; 
model tceoh = viabili t y age sex race tobacco alcohol substance ADH2/ selection stepwise; 
run; 
qUit; 
proc reg data = tce; 
model tca = viability age sex race tobacco alcohol substance ADH2/ se l ection stepwise; 
run; 
quit; 
proc reg data = tce; 
ulodel tceoh = viabili t y age sex race tobacco alcohol SUbstance/ selection 
run; 
quit; 
proc reg data = tce; 
model tca = viability age sex race tobacco alcohol substance/ selection 
run; 
quit; 
proc reg data = tce; 
run; 
quit; 







Appendix D Selected output from the stepwise regressions 
Dependent Variable: tceoh 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
ALDH2 0.4239 0.4239 6.62 0.0300 
Dependent Variable: tca 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
ALDH2 0.5454 0.5454 4865.80 12.00 0.0061 
Dependent Variable: tceoh 
REMOVED ALDH2 COVARIATE 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
ADH2 0.2295 0.2295 -4.0408 2.68 0.1360 
2 sex 2 0.1869 0.4165 -2.7588 2.56 0.1481 
Dependent Variable: tca 
REMOVED ALDH2 COVARIATE 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
sex 0.2408 0.2408 16.2350 3.17 0.1053 
2 ADH32 2 0.1837 0.4245 12.3705 2.87 0.1243 
3 viability 3 0.2194 0.6440 7.3653 4.93 0.0571 
Dependent Variable: tceoh 
REMOVED ADH3 COVARIATES 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
1 ADH2 0.2295 0.2295 -0.2140 2.68 0.1360 
2 sex 2 0.1869 0.4165 0.1395 2.56 0.1481 
Dependent Variable: tca 
REMOVED ADH3 COVARIATES 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
sex 0.2408 0.2408 2.2048 3.17 0.1053 
Dependent Variable: tceoh 
REMOVED ADH2 COVARIATE 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Entered Removed Vars In R-Square R-Square C(p) F Value Pr > F 
sex 0.2216 0.2216 1.5995 2.56 0.1439 
Dependent Variable: tca 
REMOVED ADH2 COVARIATE 
Summary of Stepwise Selection 
Variable Variable Number Partial Model 
Step Ente red Removed Vars In R-Square R-Square C(p) F Value Pr > F 
sex 0.2408 0.2408 1.3766 3.17 0.1053 
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